Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell lymphoma, accounting for 35% of all non-Hodgkin lymphoma cases. Molecularly and clinically, DLBCL is a heterogeneous disease in which immunochemotherapy cure up to 60% of patients.

To understand the genetic bases of this heterogeneity, this research team recently published a comprehensive genetic analysis that allowed the discovery of 5 genetically-defined DLBCL subtypes through integration of recurrent mutations, somatic copy number alterations and structural variants. Each of the identified genetic DLBCL subtypes with their specific molecular features provided novel insights into pathogenesis, risk prediction and combination treatment strategies.

The objective of this 2-year project is to expand mechanistic knowledge from a genomic and structural point of view on this disease, considered of important medical need to identify new treatments aimed at high-need patients.